Use of Immunosuppressive Agents for Treatment of Age-related Macular Degeneration (AMD) and Diabetic Retinopathy
Posted Jul 11 2010 5:00pm
Description of Invention: AMD belongs to a group of disorders in which the immune system may play an important role. This invention discloses that patients with AMD gain additional therapeutic benefit from combination treatment of immunosuppressive agents and standard-of-care in comparison to standard-of-care alone. This invention slows the progression of choroidal neovascularization (CNV) and may have implications for related pathologies, including diabetic retinopathy. Clinical data from a small, randomized pilot clinical trial are available.
A method of treatment for AMD.
A method of treatment for diabetic retinopathy.
A method of treatment for diseases associated with CNV.
Likely to be synergistic with existing therapeutics.
May enable repurposing of some exiting immunosuppressive agents.
Development Status: In clinical trials
Inventors: Robert B Nussenblatt (NEI) Frederick L Ferris (NEI)
Collaborative Research Opportunity: The National Eye Institute, Laboratory of Immunology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of immunosuppressive agents in the treatment of age related macular degeneration. This is in light of new findings that immune mechanisms appear to be central to the expression of the clinical disease we know as AMD. Please contact Alan Hubbs, Ph.D. at 301-594-4263 or firstname.lastname@example.org for more information.
Portfolios: Internal Medicine Internal Medicine - Therapeutics Ophthalmology Ophthalmology - Therapeutics
For Additional Information Please Contact: Norbert Pontzer Ph.D., J.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 23, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5502 Fax: 301-402-0220